In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
NPR
|
March 18, 2026
Regaining Function After Spinal Cord Injury: A New Path Forward? Dr. Adam Rogers, CEO, NervGen Pharma
On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s…
For more
The Scientist
|
February 7, 2026
From Discovery to Therapy: The Rise of Reprogrammed Tregs
Nobel Prize winner Shimon Sakaguchi, a pioneer in regulatory T cell (Treg) biology, discusses the path from early observations to…
For more
WGN-TV
|
February 5, 2026
New drug may help spinal cord injury patients regain function and hope
There is a new hope for people with spinal cord injuries. Doctors are using an experimental, easy to deliver drug,…
For more
The New York Times
|
January 9, 2026
Nothing Eased the Pain in His Chest. What Was Causing It?
Doctors ruled out a heart attack, but the patient had a sense that something was very wrong. The 52-year-old man…
For more
Investor’s Business Daily
|
January 8, 2026
Biotech Stocks’ Dark Winter Is Over. What That Means For Investors.
The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by…
For more
Fierce Pharma
|
January 6, 2026
3 biopharma CEOs explain why they are ‘authentically optimistic’ for 2026
While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would…
For more
Forbes
|
December 19, 2025
This Company’s Drug May Help Regenerate Injured Spinal Cord
Every year, around 18,000 Americans will suffer a traumatic spinal cord injury. This can lead to a number of complications,…
For more
STAT News
|
December 16, 2025
Ambros Therapeutics, Ramaswamy’s latest startup, launches with plans for pain treatment
Ramaswamy’s latest startup, Ambros Therapeutics, launched Tuesday with plans to develop a treatment for a rare form of the chronic…
For more
BioXconomy
|
December 12, 2025
Reflecting on the biotech funding landscape of 2025 and looking ahead to 2026
Ahead of JP Morgan Healthcare Conference and Biotech Showcase, industry leaders gathered to reflect on the year’s developments and share…
For more
New York Post
|
November 7, 2025
My infant son died of a rare disorder — I wish his doctors had run this cheap test sooner
Jordan Kruse realized something was wrong with her newborn, Pruitt, hours after bringing him home from the hospital last year….
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
